The intricate mechanisms underlying cancer progression often involve dysregulated signaling pathways. For researchers dedicated to unraveling these complexities and developing targeted treatments, specific chemical compounds are indispensable tools. Crizotinib (CAS 877399-52-5) is one such compound, widely recognized for its potent inhibitory effects on the ALK and c-MET kinase pathways. Its scientific merit lies in its ability to selectively target these critical oncogenic drivers, making it a highly sought-after pharmaceutical intermediate for academic and industrial research.

Crizotinib's primary function is to inhibit the tyrosine kinase activity of both ALK and c-MET. ALK, or Anaplastic Lymphoma Kinase, is a receptor tyrosine kinase that, when aberrantly activated through gene rearrangements or mutations, drives the growth of certain cancers, notably specific subtypes of non-small cell lung cancer (NSCLC). Similarly, the MET proto-oncogene encodes for the receptor tyrosine kinase known as c-MET, which is frequently overexpressed or mutated in various solid tumors, promoting tumor cell proliferation, survival, invasion, and angiogenesis.

By inhibiting these key kinases, Crizotinib effectively halts the downstream signaling cascades that fuel cancer cell growth. This targeted action makes it an invaluable asset for scientists investigating the roles of ALK and MET in oncogenesis. Researchers frequently buy Crizotinib for in-vitro assays that measure kinase activity, cell proliferation, cell cycle arrest, and induction of apoptosis. Its well-defined IC50 values for ALK and c-MET (approximately 4 nM and 25 nM, respectively) provide a solid foundation for experimental design and interpretation.

Furthermore, Crizotinib's efficacy extends to in-vivo models, where it has demonstrated significant antitumor activity in xenograft studies. This translates into its importance as a pharmaceutical intermediate for drug development pipelines aimed at creating effective cancer therapies. Procurement managers seeking reliable sources for this compound often turn to specialized chemical suppliers and manufacturers. When you choose to buy Crizotinib from a trusted provider, you ensure the purity and consistency necessary for scientifically valid results and successful development of new treatments.

In summary, Crizotinib's scientific value is profound, offering a direct means to study and target the ALK and c-MET pathways. Its utility as a pharmaceutical intermediate makes it essential for ongoing research in oncology. For those requiring this critical compound, sourcing from a reputable supplier that guarantees quality and availability is key to advancing cancer research and therapeutic innovation.